A1C outranks cholesterol
Fountain Life’s AI pipeline reportedly analyzed ~200GB of imaging/genomic data per person and flagged hemoglobin A1C as the top heart‑disease biomarker — outranking traditional cholesterol metrics. This finding arrived as big vendors push health copilot tools (Microsoft’s Copilot Health; Amazon expanding Health AI) — signaling real momentum for multimodal clinical analytics in 2026. (x.com) (technologyreview.com)
Fountain Life lists Peter H. Diamandis and Tony Robbins as co‑founders and is led operationally by CEO Dr. Bill (Bill) Kapp. (fountainlife.com) The company issued a January 6, 2026 press release saying its platform now aggregates what it calls “15+ billion clinical data points” to support its reported outcomes. (prnewswire.com) Fountain Life markets an on‑platform AI called Zori (Zori AI Medical Expert) that the company says continuously analyzes members’ clinical and everyday health data and surfaces personalized insights inside its app. (fountainlife.com) In August 2025 Fountain Life closed an $18 million financing round led by EOS Ventures, funding the company’s planned clinic expansion into U.S. cities including Houston, Los Angeles and Miami. (techcrunch.com) Independent coverage of Fountain Life’s service model notes an APEX membership price in the range of £16,000 (about $20,000) per year for the premium package referenced in recent profiles. (thehumanwareproject.com) A March 30, 2026 MIT Technology Review analysis of AI health tools urged rigorous independent testing and warned against relying solely on vendor‑led evaluations before clinical deployment. (technologyreview.com)
